# A Single-blinded, Randomized, Placebo Controlled Phase II Trial of Prophylactic Treatment With Oral Azithromycin Versus Placebo in Cancer Patients Undergoing Antineoplastic Treatment During the Corona Virus Disease 19 (COVID-19) Pandemic

> **NCT04369365** · PHASE2 · COMPLETED · sponsor: **Prof. Dr. Matthias Preusser** · enrollment: 74 (actual)

## Conditions studied

- COVID

## Interventions

- **DRUG:** Azithromycin 500 milligram (mg) oral Tablet
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04369365
- **Lead sponsor:** Prof. Dr. Matthias Preusser
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-04-27
- **Primary completion:** 2021-06-15
- **Final completion:** 2021-06-15
- **Target enrollment:** 74 (ACTUAL)
- **Last updated:** 2022-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04369365

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04369365, "A Single-blinded, Randomized, Placebo Controlled Phase II Trial of Prophylactic Treatment With Oral Azithromycin Versus Placebo in Cancer Patients Undergoing Antineoplastic Treatment During the Corona Virus Disease 19 (COVID-19) Pandemic". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT04369365. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*